Study Data from National Cancer Institute (NCI) Provide New Insights into Carcinomas

Strategic Insights -

Recent research findings from a study conducted by the National Cancer Institute (NCI) have shed new light on the treatment of carcinomas. The study, which was published in Future Oncology, explored the use of sacituzumab govitecan (SG), a TROP2-directed antibody-drug conjugate, in combination with atezolizumab, an immunotherapeutic agent. The research aimed to investigate the efficacy of this treatment combination in patients with rare genitourinary tumors.

Key Takeaways:

  • The study found that sacituzumab govitecan (SG) monotherapy demonstrated activity in multiple solid tumors, including metastatic breast and bladder cancer.
  • SG is a TROP2-directed antibody-drug conjugate with a payload of SN-38, a topoisomerase inhibitor.
  • The combination of SG and atezolizumab showed promise in treating rare genitourinary tumors, such as bladder/urinary tract adenocarcinoma/urachal adenocarcinoma, squamous cell carcinoma, or high-grade neuroendocrine carcinoma; renal medullary carcinoma; and penile squamous cell carcinoma.
  • The study was designed to evaluate the safety and efficacy of SG monotherapy or concomitant SG plus atezolizumab in locally advanced/metastatic bladder/urinary tract adenocarcinoma/urachal adenocarcinoma, squamous cell carcinoma, or high-grade neuroendocrine carcinoma; renal medullary carcinoma; and penile squamous cell carcinoma.
  • The research included a phase 2 trial of SG monotherapy or concomitant SG plus atezolizumab in patients with rare genitourinary tumors.
  • The study has been peer-reviewed and the results provide new insights into the treatment options for carcinomas.

Statistics:

  • Sacituzumab govitecan (SG) is a TROP2-directed antibody-drug conjugate with a payload of SN-38, a topoisomerase inhibitor.
  • The combination of SG and atezolizumab was evaluated in a phase 2 trial of patients with rare genitourinary tumors.
  • The study included patients with locally advanced/metastatic bladder/urinary tract adenocarcinoma/urachal adenocarcinoma, squamous cell carcinoma, or high-grade neuroendocrine carcinoma; renal medullary carcinoma; and penile squamous cell carcinoma.
  • The research was conducted by the National Cancer Institute (NCI) in collaboration with Gilead Sciences through a Cooperative Research and Development Agreement.

Sources:

  • A Phase 2 Study of Sacituzumab Govitecan With or Without Atezolizumab In Rare Genitourinary Tumors (Smart) - Design and Rationale. Future Oncology, 2025.
  • NewsRx. Study Data from National Cancer Institute (NCI) Provide New Insights into Carcinomas [A Phase 2 Study of Sacituzumab Govitecan With or Without Atezolizumab In Rare Genitourinary Tumors (Smart) - Design and Rationale]. Immunotherapy Weekly. July 16, 2025; p 1591.